Aadi Bioscience, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a phase 2 trial data highlight potential for synergy to enhance anti-cancer effects and overcome resistance in non-small cell lung cancer los angeles , april 9, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance...

Subgroup experienced efficacy and safety consistent with overall study population advanced malignant pecoma tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in ampect additional data presented highlight nab-sirolimus as potential approach for mtor-driven gynecologic cancers los angeles , march 17, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced patients in the ampect trial whose malignant perivascular epithelioid cell tumor (pecoma) had gynecologic origins experienced efficacy and safety consistent with the overall study population...

Fyarro® sales of $6.3 million for q4 2023 and $24.4 million for fy 2023 representing year-over-year growth of 21% and 60%, respectively registration-directed precision1 trial of nab-sirolimus in solid tumors with tsc1 or tsc2 inactivating alterations  on track to complete enrollment by may; two-thirds interim analysis planned for q3 2024 phase 2 trials in endometrial cancer and neuroendocrine tumors (nets) actively enrolling patients conference call to be held today at 8:30 am edt los angeles , march 13, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced financial results for the fourth quarter and full-year ended december 31, 2023, and highlighted recent corporate progress...

Company to host conference call and webcast on march 13, 2024 los angeles , march 6, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced that it will host a conference call and live webcast on wednesday, march 13, 2024 at 8:30 am et (5:30 am pt) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates. conference call information  participants may access a live webcast of the call on the "investors & news" page of the aadi bioscience website at  aadibio.com.

Los angeles , march 5, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor-driven cancers, today announced poster presentations at the 2024 american association for cancer research (aacr), taking place april 5-10, 2024, in san diego, ca. aacr poster presentation details are below: title: " evaluation of nab-sirolimus in combination with fulvestrant or pi3k pathway inhibitors to overcome resistance in breast cancer cell lines " session title: reversal of drug resistance 2 location: poster section 25, board number 6 abstract number: 7196 date/time: wednesday apr 10, 2024, 9:00 am - 12:30 pm presenting author: shihe hou, phd title: "correlation of nab-sirolimus tumor drug levels and improved tumor suppression in kras g12c non-small cell lung cancer xenografts treated with nab-sirolimus in combination with kras inhibitors" session title: targeting kinase and erk pathways location: poster section 46, board number 3 abstract number: 6486 date/time: tuesday apr 9, 2024 1:30 pm - 5:00 pm presenting author: shihe hou, phd more information can be found on the aacr meeting website.

Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Aadi Bioscience (NASDAQ: AADI ) stock is falling on Friday following the release of interim clinical trial data from its PRECISION1 study. This clinical trial covers the use of nab-sirolimus as a treatment for patients with TSC1 or TSC2 inactivating alterations.

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President, Investor Relations and Corporate Communications Scott Giacobello - CFO Dave Lennon - President and CEO Loretta Itri - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen Joe Catanzaro - Piper Sandler Roger Song - Jefferies Ahu Demir - Ladenburg Thalmann Operator Good day, and thank you for standing by. Welcome to the Aadi Bioscience Third Quarter 2023 Earnings Conference Call.

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.73 per share a year ago.

Today, we take our first look at a small cap oncology name called Aadi Bioscience, Inc. The firm's main asset is a product called FYARRO which is approved for one rare indication and is being evaluated for additional tumor types. An investment analysis follows in the paragraphs below.

LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.

LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.  The details of the poster presentations are below: Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I) " Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PM Session Title: Phase II and Phase III Clinical Trials in Progress  Presentation Number: CT057 Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts" Date and Time: Tuesday, April 18, 2023, 1:30 - 5:00 PM Session Category: Clinical Research Excluding Trials Session Title: Poster Combination Therapies for Cancer Presentation Number: 5484 Title: " Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations " Date and Time: Wednesday, April 19, 2023, 9:00 AM - 12:30 PM Session Category: Clinical Research Excluding Trials Session Title: Late-Breaking Research: Clinical Research 3 Presentation Number: LB288 Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR.